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Abstract
Background: Buruli ulcer (BU) is an infection of the subcutaneous tissue leading to chronic necrotizing skin ulcers. The
causative pathogen, Mycobacterium ulcerans, grows best at 30uC–33uC and not above 37uC. We explored the safety,
tolerability and efficacy of phase change material (PCM), a novel heat application system for thermotherapy of BU.
Methodology/Principal Findings: In a prospective observational single centre proof-of-principle trial in Ayos/Cameroon, six
laboratory reconfirmed patients with ulcerative Buruli lesions received 28–31 (ulcers #2 cm) or 50–55 (ulcers .2 cm) days
of thermotherapy with the PCM sodium acetate trihydrate as heat application system. This PCM is widely used in
commercial pocket heat pads, it is easy to apply, rechargeable in hot water, non-toxic and non-hazardous to the
environment. All patients enrolled in the trial completed treatment. Being completely mobile during the well-tolerated heat
application, acceptability of the PCM bandages was very high. In patients with smaller ulcers, wounds healed completely
without further intervention. Patients with large defects had skin grafting after successful heat treatment. Heat treatment
was not associated with marked increases in local inflammation or the development of ectopic lymphoid tissue. One and a
half years after completion of treatment, all patients are relapse-free.
Conclusions/Significance: Our reusable PCM-based heat application device appears perfectly suited to treat BU in endemic
countries with limited resources and infrastructure.
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Introduction
Buruli ulcer (BU) is a chronic necrotizing disease of skin and soft
tissue caused by Mycobacterium ulcerans [1]. The disease starts as a
subcutaneous nodule, papule or plaque that eventually ulcerates
and progresses over months to years. In BU lesions, clumps of
extra-cellular acid-fast organisms surrounded by areas of necrosis
are found primarily in subcutaneous fat tissue [2]. M. ulcerans
produces a macrolide toxin, mycolactone, which is associated with
tissue destruction and local immunosuppression [3]. BU has been
reported in .30 countries, but the major burden lies on children
living in remote areas of West Africa associated with swamps and
stagnant water bodies. Traditionally wide excision of the infected
tissue alone was the standard treatment for BU. This is hampered
by traumatic interventions, high cost and very high recurrence
rates [4]. Chemotherapy with streptomycin and rifampicin is
currently re-evaluated as an adjunct treatment to surgery and as a
therapy in its own right [5,6,7,8].
M. ulcerans differs from most other pathogenic mycobacteria in
that it grows best at 30–33uC and not above 37uC [9]. This
characteristic feature of the pathogen was first used for therapeutic
purposes in the early 1970s. Meyers et al. treated 8 patients from
Zaire maintaining a temperature of approximately 40uC in the
ulcerated area for a mean duration of 68 days [10]. There was no
evidence of local recurrence during follow-up periods of up to 22
months. Based on this impressive success rate, WHO guidelines
listed the application of heat as a treatment option for BU [11].
However, the heat application devices employed so far were
impractical in most endemic countries. Here we describe the use of
a cheap and easy to apply phase change material (PCM) device
suitable for thermotherapy of BU in countries with limited
resources.
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Study participants
Eligibility criteria for participants and case
definition. All patients between 6 and 30 years of age with an
ulcer at the lower or upper arm or leg with a diameter of up to
12 cm suggestive for BU on clinical grounds in the catchment area
of the Buruli treatment center Ayos/Cameroon were candidates
for inclusion in the study. They were not admitted to the study if
any of the following criteria were present: (1) clinical signs and
symptoms of communicable diseases other than BU (fever, weight
loss, night sweats, persistent cough, jaundice, pulmonary or
myocardial dysfunction, CNS involvement, ascites, pleural
effusion), (2) clinical signs and symptoms of non-communicable
diseases (myocardial, pulmonary, renal, CNS) and (3) inability to
confirm BU using laboratory methods.
A BU case was defined as a patient with an ulcer diagnosed as
BU on clinical grounds and positive results in at least two of the
three laboratory tests (PCR, detection of AFB on microscopy and
histopathology) performed.
Laboratory confirmation of clinical diagnosis. On day 0
four swabs from the undermined edges and one diagnostic biopsy
were taken from all patients enrolled into the trial on clinical
grounds. A second set of biopsies was taken in week 4 of
thermotherapy to assess histopathological changes in response to
heat treatment. All samples were investigated by microscopy for
acid-fast bacilli (AFB) after Ziehl Neelsen (ZN) staining and by
IS2404 real-time PCR [12]. Histopathological changes typical for
BU [12] were recorded in the initial biopsies and the follow-up
biopsies in week 4 of thermotherapy.
Immediately after performing the punch biopsies, tissue samples
were fixed in 4% neutral-buffered PFA (paraformaldehyde) for
24 h and subsequently transferred to 70% ethanol for short term
storage and transport. Biopsies were dehydrated, embedded in
paraffin, cut into 5 mm thin sections and retrieved on glass slides.
After dewaxing and rehydration, sections were stained with
haematoxylin/eosin (HE) and ZN. Immunohistochemistry (IHC)
was performed with antibodies against Elastase (polymorphonu-
clear neutrophils [PMNs]; Dako) and CD3 (T lymphocytes; Dako).
Staining was performed using Vector NovaRED and haematox-
ylin.
The setting and location where the data were
collected. Volunteers were recruited in the catchment area of
the Buruli treatment center at the hospital Ayos/Cameroon,
identified by active and passive case detection. The treatment
center has a longstanding collaboration with and is supported by
Leprosy Relief Emmaus-Switzerland (ALES). It maintains a very
well equipped and functioning operation theatre, wards for pre-
and postsurgical care, physiotherapy and a school which is of
importance because the majority of patients with this disease are
children and convalescence after excision of ulcers and skin
grafting takes many months in the majority of patients. Dr. A. Um
Boock, the director of the ALES Bureau Re ´gional pour l’Afrique,
and his team are very experienced in the diagnosis and
management of patients with Buruli ulcer, including surgery and
skin grafting.
Ethical approval and informed consent. The protocol was
approved by the National Ethics Committee of Cameroon and the
Ethics Committee of the University Hospital, Heidelberg,
Germany. Patients were enrolled in the study only after
informed written consent was obtained from them or their care
providers.
Interventions
Heat application. Commercially available plastic bags filled
with the PCM sodium acetate trihydrate were used. Starters were
placed in the bags to initiate the crystallisation process (Fig. 1). Size
of filled bags is 21 cm615 cm62 cm with an average weight of
800 g. The melting temperature of the PCM sodium acetate
trihydrate is 58uC. The unique feature of PCM is its thermal
energy storing capacity combined with an almost constant
temperature during the liquid-solid phase transition. This
property is widely used in commercial pocket heat pads.
After cleaning and sterile dressing of the ulcers a heat sensor
connected to a data logger (testo 177-T3, testo AG, Lenzkirch,
Germany) was placed on healthy skin at the edge of the ulcer. The
area of contact between skin and PCM packs was protected by tube
gauze and a layer of elastic bandage to lower the PCM working
temperature from 58uC to the therapeutic target temperature of
40uC at skin surface (Fig. 1). Temperatures of #58uC do not cause
burns when not applied for prolonged periods of time. Skin
temperatures of up to 43uC were accepted and well tolerated for
short intervals of time immediately after mounting the PCM
bandage. Theaffected skin(ulcer/oedema/induration)plusa safety
margin of several centimeters was covered by one to four PCM
packspersessiondependingonthesizeofthetotalareatobetreated
(Fig. 2). The PCM packs were fixed with several layers of elastic
bandage. A thermal insulation layer, commercially available to
insulate hot water pipes, was used to reduce heat loss to the
environment and to reinforce positioning of the PCM packs (Fig. 1).
Thisallowed patients to move around freely. The 24 hours protocol
was as follows: 8.00: Clinical progress assessment, cleaning and
dressing of ulcers and renewal of PCM-packs, photo documentation
at, on average, 3 day intervals. 12.00: Removal of PCM-packs,
dressing of the wound to protect from contamination during a
5 hour pause of heat treatment, skin care with fatty cream. 17.00:
Additional wound cleaning and dressing, if needed, renewal of
PCM-packs. 22.00: Renewal of PCM-packs.
Clinical observations (appearance of the ulcer and the surround-
ingheat exposed skin, overallclinical assessment of the patient) were
recorded daily at the above mentioned time points on case record
forms (CRF). Temperature at the skin surface was automatically
Author Summary
Buruli ulcer is an infection of the subcutaneous tissue
leading to chronic necrotizing skin ulcers. The causative
pathogen, Mycobacterium ulcerans, grows best at 30uC–
33uC and not above 37uC, and this property makes the
application of heat a treatment option. We achieved a
breakthrough in heat treatment of Buruli ulcer by
employing the phase change material sodium acetate
trihydrate as a heat application system for thermotherapy,
which is widely used in commercial pocket heat pads. It is
easy to apply, rechargeable in hot water, non-toxic and
non-hazardous to the environment. Six laboratory recon-
firmed patients with ulcerative Buruli lesions were
included in the proof-of-principle study and treated for
four to six weeks. In patients with small ulcers, wounds
healed completely without further intervention. Patients
with large defects had skin grafting after successful heat
treatment. Heat treatment was not associated with marked
increases in local inflammation or the development of
ectopic lymphoid tissue. One and a half years after
completion of treatment, all patients are relapse-free.
The reusable phase change material–based heat applica-
tion device appears perfectly suited for use in remote
Buruli ulcer–endemic areas of countries with limited
resources and infrastructure.
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carried by the patients. Temperature data were transferred daily to
a notebook and checked for therapeutic and safety margins (testo
software ComSoft 3.4, testo AG, Lenzkirch, Germany).
Patientswithsmallulcersandwithoutsignificantoedema(patients
1, 2, 3) received heat treatment for 28–31 days, patients with large
ulcers and/or significant oedema (patients 4, 5, 6) for 50–55 days.
Study objectives
In the current study we tested the hypotheses that
(1) PCM-based heat application is safe and comfortable for
patients
(2) with PCM based heat application the results of the thermo-
therapy study of Meyers et al [10] can be reproduced, i.e.
primary healing of Buruli ulcer without relapse can be achieved
Primary outcomes
(1) Proportion of patients completing 28–31 days of heat
treatment in patients with small ulcers (#2 cm) or 50–55
days in patients with large ulcers (.2 cm) and ulcers with
prominent surrounding oedema
(2) Proportion of patients cured 6 months after completing heat
treatment (including skin grafting where necessary). Cure is
defined as complete closure of the wound by epithelialisation
or scarification or by skin graft.
(3) Proportion of patients who are recurrence free 18 months
after completing heat treatment
Secondary endpoint
Histopathological responses in week 4 of thermotherapy
compared to reference samples at day 0.
Results
Participant flow
Seven patients with ulcers suggestive for BU on clinical
grounds were recruited by active and passive case detection. In
six of the seven patients enrolled the diagnosis was laboratory
confirmed.
Figure 1. Mounting of the PCM-based heat application system and temperature monitoring device. (A) PCM pack and bandage
mounted for treating an ulcer on the lower limb (patient 2) and temperature monitoring system, (B) PCM pack with sodium acetate trihydrate in the
fluid phase before initiating the crystallisation process with the starter (red), sodium acetate trihydrate in the solid phase after the stored heat has
been discharged, (C) temperature monitoring system with the sensor connected to the data logger to record the temperature at the skin surface as
part of the clinical trial documentation. This will not be needed when the device is put into routine use.
doi:10.1371/journal.pntd.0000380.g001
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We extended the total duration of heat application of large
ulcers (.2 cm) and ulcers with prominent surrounding oedema
from 4 week to 50–55 days and did not, as originally planned, treat
small and large ulcers equally for 4 weeks only. This was done
even though all ulcers appeared clinically healed after 4 weeks of
heat treatment, independent of size and surrounding oedema. This
decision was taken on the basis of the results of the punch biopsies
in week 4 of thermotherapy showing residual AFB with intact rod-
shaped appearance.
Recruitment and follow-up
Eligible patients were recruited between February 28, 2007
and March 3, 2007. Patients stayed in the hospital during the
course of heat treatment and thereafter until the wound was
closed (patients with small ulcers; patients 1, 2, 3, 4,) or skin
grafted (patients with large ulcers; patient 5 and 6). All patients
were followed up until 18 months after completion of heat
treatment.
Baseline data
The age range of the seven patients enrolled was six to 21 years.
Three patients had single ulcers on the upper and four had single
ulcers on the lower extremities. Medical history and physical
examination revealed no significant health problem other than
BU. In six out of seven patients enrolled in the study on clinical
grounds, diagnosis was laboratory confirmed. The unconfirmed
patient was excluded from the analysis (Fig. 2).
Outcomes
All patients enrolled into the trial completed treatment. In all
patients temperatures at the lesion and over a wide margin of
healthy looking skin were maintained above $39uC for between
8.4 and 13.2 hours and $40uC for between 4.4 and 9.3 hours per
day (Fig. 2). Undermined margins collapsed between day 1 and
day 3. Epithelialization started in all patients between 4 and 11
days after the start and was almost completed in patients 1, 2, and
3 at the end of heat treatment (Fig. 2 and Fig. 3). In particular in
patients with oedematous lesions (patients 4, 5) white discharge
Figure 2. Baseline data, heat treatment schedules and results.
doi:10.1371/journal.pntd.0000380.g002
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lengths of time. The two patients with large defects (patients 5 and
6) had skin grafting after completion of heat treatment (Fig. 3B).
All six reconfirmed patients were healed and relapse-free 18
months after completion of treatment.
In the punch biopsies taken prior to start of treatment,
histopathological changes characteristic for BU, such as fat cell
ghosts, deep dermal necrosis and/or psoriasiform epidermal
hyperplasia, were found in six patients (Fig. 2). All patients yielded
positive semi-quantitative IS2404 real-time PCR results. AFBs
Figure 3. Healing of Buruli ulcers under PCM-based heat treatment and long term results. (A) Patient 2, (B) patient 5: Progress of healing
during heat treatment. Note in particular early onset of epithelialisation. Far right follow-up 12 months after completion of heat treatment. Patient 5
(B) after skin grafting.
doi:10.1371/journal.pntd.0000380.g003
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included in the study.
Analysis of serial sections of punch biopsies taken at day 0 and
in week 4 of thermotherapy showed, that heat treatment was not
associated with marked increases in local inflammation, the
development of ectopic lymphoid tissue or haemorrhages. At both
time points small numbers of both polymorphonuclear cells as
members of the innate and T cells as members of the adaptive
immune system were present, with polymorphonuclear cells
mainly located around necrotic areas and T cells more confined
to areas close to vessels in the upper dermis. Only the lesion of
patient 3 contained both on day 0 and in week 4 of thermotherapy
mixed cellular infiltrates, which were much more pronounced than
in typical untreated BU lesions.
Safety and tolerability of PCM-based heat treatment,
adverse events
The heat treatment procedure was very well tolerated by all
patients. Patients with one (patients 1, 2, 3, 4) and with two PCM
packs (patient 5) could move around freely and did not feel
unacceptably disturbed during their daily activities nor during
sleep at night. Patient 6 with four PCM packs also walked with
acceptable restrictions and slept largely undisturbed. None of the
patients and their guardians requested termination of treatment at
any time. Temperatures between 40–43uC were observed only for
short intervals of time immediately after mounting of the PCM
packs without causing unacceptable discomfort. Only initially a
few small blisters were occasionally observed. With a simple
patient-controlled method the therapeutic target temperature of
40uC at skin surface was quickly reached and maintained without
further side effects.
Discussion
Successful treatment of BU with heat has been reported in
individual patients and small case series since 1950
[10,13,14,15]. This has not been carried further into clinical
research and practice due to the fact that available heat
application systems were cumbersome and not suited for use in
developing countries. We achieved a break through by
employing PCM packs as a cheap heat application system
which is rechargeable in hot water, non-toxic and non-hazardous
to the environment. In this proof-of-principle study we
demonstrated that our heat application system is easy to use
and allows the patient to move freely.
Family members and the hospital community accepted the
treatment very well and favoured it over other treatments
currently offered (surgery, antibiotics). Nurses quickly adopted
the techniques of mounting the PCM packs and of recharging the
packs in boiling water. The only side effects observed were
sensation of excessive heat for a short period after applying the
PCM packs. Lowering of the temperature at the skin surface by an
elastic bandage interposed between tube gauze and PCM packs
reliably prevented skin irritation and development of blisters,
which may occur if the initial temperature at skin surface is less
rigorously controlled.
With our PCM-based heat application system we reproduced
the excellent results of the thermotherapy study of Meyers’ group
in 1974 [10] with significantly shorter heat application times both
with respect to length of heat treatment per day (close to 24 hours
[39uC–40.5uC] vs a mean of 10 hours, range 8.4–13.2 hours
[$39uC]) and to total heat application time (28 to 115 days vs 28
to 55 days). Since both systems worked at the same temperature
range measured at skin surface, the minimum length of heat
application to achieve healing of BU appears to be in the range of
our heat treatment schedule or even shorter.
The initial clinical improvement of ulcerative lesions in our
series was as fast as in the patient series of Meyers et al. As early as
three days after initiation of heat treatment undermined ulcer
margins collapsed and the skin attached to the underlying
subcutaneous tissue with re-epithelialization starting at the edges.
Discharge of the wound decreased over various lengths of time.
Firm attachment of the affected skin was complete only after
discharge stopped. By using heat treatment alone no viable tissue is
lost and even the overarching margins at undercutting edges are
often rescued. Lesions were clinically inactive in all of our patients
with very good granulation and re-epitheliazation responses after
28 days of heat treatment. In one of our patients (patient 6) non-
viable tissue extended far beyond the ulcerated area, which had to
be excised before skin grafting. In this patient and one other
patient with a large defect (patient 5) skin grafting was performed
after a good granulation response had been achieved. Currently,
all our patients are relapse-free 18 months after completion of heat
therapy.
Rifampicin/streptomycin chemotherapy of BU is associated
with the development of ectopic lymphoid tissue in the lesions
[16]. In some patients, effects reminiscent of the immune
reconstitution syndromes observed in tuberculosis and leprosy
patients after highly active antiretroviral therapy [17] are
observed. In contrast, heat treatment did not lead to massive
increases in local inflammation and this less vigorous response may
favour rapid re-epithelialization. Also haemorrhages, which are
regarded as negative indicators for uncomplicated wound healing
[18] were not observed.
Results of two pilot studies, the study of Meyers et al. in the
1970s [10] and our study, demonstrate that heat is a highly
efficacious therapy for M. ulcerans disease. Use of PCM packs
represents a break through for thermotherapy with respect to its
practicality in endemic areas with poor infrastructure. Further
optimization of the heat treatment schedule should make it
suitable for community application.
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